Neutralizing antibody evasion of SARS-CoV-2 JN.1 derivatives KP.3, KP.3.1.1, LB.1, and XEC. Sano K, Miyakawa K, Kato H, Kimura Y, et al. Vaccine 2025;62:127472.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sano K, Miyakawa K, Kato H, Kimura Y, et al. Neutralizing antibody evasion of SARS-CoV-2 JN.1 derivatives KP.3, KP.3.1.1, LB.1, and XEC. Vaccine 2025;62:127472.
PMID: 40639176